Urothelial Carcinoma

Concomitant use of statins improved survival among people with cancer treated with immune checkpoint inhibitors, according to results of a meta-analysis.

The FDA has approved nivolumab and hyaluronidase-nvhy for subcutaneous injection in adults with solid tumors in which nivolumab is indicated, according to a press release.

Immunotherapy utilization for treatment of advanced kidney or bladder cancers varied by patients’ race or socioeconomic status, according to study results.

Gilead Sciences announced its intention to voluntarily withdraw the accelerated approval for sacituzumab govitecan-hziv for treatment of certain patients with advanced bladder cancer.

Rates of next-generation sequencing have increased for individuals with metastatic prostate cancer or advanced urothelial carcinoma over the past several years, but more than half of these individuals still do not undergo testing.

The FDA approved nivolumab in combination with cisplatin and gemcitabine for the first-line treatment of adults with unresectable or metastatic urothelial carcinoma, according to a press release.

NASHVILLE, Tenn. — Pavlos Msaouel, MD, PhD, received the Kidney Cancer Association’s Christopher G. Wood Rising Star Award.

Pembrolizumab significantly improved DFS compared with observation for the adjuvant treatment of patients with localized muscle-invasive urothelial carcinoma and locally advanced urothelial carcinoma, according to the agent’s manufacturer.

The addition of nivolumab to cisplatin-based chemotherapy improved outcomes compared with standard regimens for certain patients with advanced urothelial carcinoma, according to the agent’s manufacturer.

CHICAGO — Post-hoc analyses of the JAVELIN Bladder 100 trial confirmed the acceptable long-term safety of avelumab first-line maintenance for advanced urothelial carcinoma, according to a presentation at ASCO Annual Meeting.